CannabisNewsBreaks – Veritas Pharma Inc.’s (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) CTL Subsidiary Inks Letter of Intent with FDI of Puerto Rico to Initiate Human Trials of CTL-X

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) recently announced that its 80% owned subsidiary, Cannevert Therapeutics Ltd. (“CTL”), signed a letter of intent with the Fundación de Investigación (“FDI”) in San Juan, Puerto Rico, to conduct the first human study of CTL-X for the treatment of pain. The study of CTL-X, CTL’s lead cannabis strain for pain, will be conducted in two stages to assess the treatment’s analgesic effects. “We are pleased to see Cannevert’s lead strain for pain is finally heading into human trials. It’s important to us to move quickly into this next phase of providing clinical proof of cannabis’ effectiveness, this after our chemical and animal assays delivered favorable results,” Veritas CEO Lui Franciosi stated in the news release.

To view the full press release, visit http://cnw.fm/CZga5

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 80% owned subsidiary Cannevert Therapeutics Ltd. (“CTL”), is advancing the science behind medical cannabis. It is the company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets. For more information, visit the company’s website at www.VeritasPharmaInc.com.

More from CannabisNewsBreaks

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Leave a Reply